Scribe Therapeutics Inc. filed an amendment for its Initial Public Offering, planning to offer 7,150,000 shares of common stock at an anticipated price range of $13.00 to $15.00 per share. The company has applied to list its common stock on the Nasdaq Global Market under the symbol "SCTX." Concurrently, Sanofi has agreed to purchase approximately $7.5 million in shares, and Eli Lilly and Company has expressed interest in purchasing shares up to 10.9% of the company's outstanding stock post-offering. Scribe Therapeutics, a clinical-stage biotechnology company, is advancing its lead product candidate STX-1150 into a first-in-human clinical trial, with initial data expected in the first half of 2027, and has other programs in preclinical development, while also noting a history of operating losses and substantial doubt about its ability to continue as a going concern.
